Company / R&D per Share
enGene Holdings Inc. R&D per Share History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.85
FY2025
5-year range
$1.01 / $23.76
FY2022-FY2025
Trend
+82.3%
vs FY2024
Sector context
#104 of 204
Health Care
What the data says
At $1.85, enGene Holdings Inc.'s r&d per share ranks #104 of 204 in the Health Care sector. Declined from $23.76 to $1.85 over the past 2 years.
Based on SEC 10-K filings.
1.85 in FY2025 with a 3-year CAGR of -57.2%.
Declined from $23.76 to $1.85 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -57.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#104 of 204 in Health CareTop 51% of 204This company $1.85 Sector average $34.99
▼
-94.7% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 82.3% year-over-year.
- Ranks #104 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.85 | +82.3% |
| FY2024 | $1.01 | -95.7% |
| FY2023 | $23.76 | +0.7% |
| FY2022 | $23.61 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026